Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
rKhVy4wWmhzjJ2ky